-
Loading metrics
Open Access
Peer-reviewed
Research Article
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
-
Mohammad Atefi ,
Contributed equally to this work with: Mohammad Atefi, Erika von Euw
Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Erika von Euw ,
Contributed equally to this work with: Mohammad Atefi, Erika von Euw
Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Narsis Attar,
Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Charles Ng,
Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Connie Chu,
Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Deliang Guo,
Affiliation Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Ramin Nazarian,
Affiliation Department of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Bartosz Chmielowski,
Affiliation Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
John A. Glaspy,
Affiliations Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Begonya Comin-Anduix,
Affiliations Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Jonsson Comprehensive Cancer Center at University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Paul S. Mischel,
Affiliations Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Roger S. Lo,
Affiliations Department of Medicine, Division of Dermatology, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America
⨯ -
Antoni Ribas
* E-mail: aribas@mednet.ucla.edu
Affiliations Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California, United States of America, Jonsson Comprehensive Cancer Center at University of California Los Angeles, Los Angeles, California, United States of America
⨯
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- Mohammad Atefi,
- Erika von Euw,
- Narsis Attar,
- Charles Ng,
- Connie Chu,
- Deliang Guo,
- Ramin Nazarian,
- Bartosz Chmielowski,
- John A. Glaspy,
- Begonya Comin-Anduix
- Published: December 14, 2011
- https://doi.org/10.1371/journal.pone.0028973